Advocacy intelligence hub — real-time data for patient organizations
Crinetics Pharmaceuticals Inc. — PHASE2, PHASE3
Crinetics Pharmaceuticals Inc. — PHASE3
Neurocrine Biosciences — PHASE2
IRCCS Azienda Ospedaliero-Universitaria di Bologna — NA
Crinetics Pharmaceuticals Inc. — PHASE2
Crenessity: FDA approved
adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH)
University of Roma La Sapienza — NA
H. Lundbeck A/S — PHASE1, PHASE2
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Adrenas Therapeutics Inc — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Crenessity
Unknown
Crenessity
(crinecerfont)Orphan drugNeurocrine Biosciences, Inc.
Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]
12.1 Mechanism of Action Crinecerfont is a selective corticotropin-releasing factor (CRF) type 1 receptor antagonist. Crinecerfont blocks the binding ...
Dyural 80-Lm
(METHYLPREDNISOLONE ACETATE, LIDOCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE, POVIDINE IODINE, ISOPROPYL ALCOHOL)Orphan drugstandardAdvanced Rx Pharmacy of Tennessee, LLC
12.1 Mechanism of Action Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical...
Federico Baronio
IRCCS Azienda Ospedaliero-Universitaria di Bologna
📍 Bologna
Irina Bancos, MD, M.D
Mayo Clinic
📍 ROCHESTER, MN
Stylianos Tsagarakis, Professor
Evaggelismos Hospital
Andreas Moraitis, MD, M.D
Corcept Therapeutics
📍 SUNNY ISLES BEACH, FL
Deborah P Merke, M.D., M.D
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
📍 BETHESDA, MD
Anand Vaidya, MD, MD, MMSc
Brigham and Women's Hospital
📍 BOSTON, MA